Ann Intern Med

1. QASEEM A, Obley AJ, Harrod CS, Wilt TJ, et al
   COVID-19 Vaccines for 2025-2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
   Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05026.
   

   >> Share

   
   
2. 
   Annals Video Summary - COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised.
   Ann Intern Med. 2026 Feb 24:e2600306VS. doi: 10.7326/ANNALS-26-00306.
   

   >> Share

   
   
3. 
   Summary for Patients: COVID-19 Vaccines for 2025-2026.
   Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05026.
   

   >> Share

   
   
4. DOBRESCU A, Pinte L, Sharifan A, Gadinger A, et al
   Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
   Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05044.
   

   >> Share

   
   

   
   BMC Pediatr

5. KARAKURT LT, Bozkurt HB, Uslu G, Bal F, et al
   Attitudes and behaviors of adolescents with asthma and their parents toward influenza and COVID-19 vaccination: barriers and facilitators of uptake.
   BMC Pediatr. 2026 Feb 26. doi: 10.1186/s12887-026-06575.
   

   >> Share

   
   

   
   BMJ

6. LOGAN M
   RFK Jr is sued by 15 US states over new childhood vaccine schedule.
   BMJ. 2026;392:s405.
   

   >> Share

   
   
7. WU S, Deng Y, Lepp T, Ask LS, et al
   Extended follow-up of invasive cervical cancer risk after quadrivalent HPV vaccination: nationwide, register based study.
   BMJ. 2026;392:e087326.
   

   >> Share

   
   
8. NOGRADY B
   Whooping cough: Vaccination rates at 10 year low in Australia after record breaking surge in cases.
   BMJ. 2026;392:s365.
   

   >> Share

   
   
9. IACOBUCCI G
   Measles: Extra funding announced for GPs who boost vaccination rates.
   BMJ. 2026;392:s358.
   

   >> Share

   
   

   
   Clin Infect Dis

10. MITHA E, Ferguson M, Wilhase AC, De Looze F, et al
    Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged >/=60 Years.
    Clin Infect Dis. 2026 Feb 27:ciag058. doi: 10.1093.
    

    >> Share

    
    
11. NELLORE A, Bajema K, Belden K, Blumberg D, et al
    IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19 infections in immunocompromised patients.
    Clin Infect Dis. 2026 Feb 25:ciag115. doi: 10.1093.
    

    >> Share

    
    
12. HOLLAND C, Le H, Levy A, Minney-Smith C, et al
    Maternal influenza vaccine reduces the risk of RSV and related respiratory hospitalisations in early infancy: an epidemiological study.
    Clin Infect Dis. 2026 Feb 25:ciag131. doi: 10.1093.
    

    >> Share

    
    

    
    J Gen Virol

13. SAITO H, Midorikawa Y, Okamura T, Mwamburi SM, et al
    Attenuation mechanisms of the P7-P8 live-attenuated cyvirus cyprinidallo2 vaccine potentially involve apoptosis non-inhibition feature: insights into virus pathogenesis.
    J Gen Virol. 2026;107:002227.
    

    >> Share

    
    

    
    J Infect Dis

14. KEGBEVI KB, Febriani Y, Sauvageau C, Ursu MM, et al
    Immunogenicity of two versus three doses of hepatitis B vaccine when administered to children aged 2-18 months: a randomized clinical trial.
    J Infect Dis. 2026 Feb 25:jiag122. doi: 10.1093.
    

    >> Share

    
    

    
    JAMA

15. ROTHMAN JM, Kwan B, Longhurst CA, Jena AB, et al
    US Newborn Hepatitis B Virus Vaccination Rates.
    JAMA. 2026 Feb 23:e260866. doi: 10.1001/jama.2026.0866.
    

    >> Share

    
    

    
    Nat Med

16. MURCIANO-GOROFF YR, Stadler ZK
    Preventive vaccines for hereditary cancer syndromes.
    Nat Med. 2026 Feb 26. doi: 10.1038/s41591-026-04248.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

17. KANG CR, Kim CB, Choe YJ, Kang IS, et al
    Emergence of Non-vaccine Serotypes and Antibiotic Resistance in Pneumococcal Carriage Among Korean Children: A Cross-sectional Study.
    Pediatr Infect Dis J. 2026 Feb 27. doi: 10.1097/INF.0000000000005206.
    

    >> Share

    
    
18. ZHANG X, Balasubramani GK, D'Agostino HEA, Liu H, et al
    The Impact of Maternal Influenza Infection and Vaccination During Pregnancy on Birth Outcomes.
    Pediatr Infect Dis J. 2026 Feb 25. doi: 10.1097/INF.0000000000005194.
    

    >> Share

    
    

    
    PLoS One

19. MAHDEEN AA, Hossain I, Masum MHU, Rabbi TMF, et al
    A novel mRNA-based multiepitope vaccine candidate against Cryptosporidium hominis and Cryptosporidium parvum employing reverse-vaccinology and immunoinformatics approaches.
    PLoS One. 2026;21:e0343643.
    

    >> Share

    
    
20. MOLTOT T, Gebreegziabher ZA, Walle AD, Nigussie M, et al
    Second-dose measles vaccination coverage and associated factors among children aged 19 to 35 months in Debre Birhan city, Ethiopia, 2024: A community-based cross-sectional study.
    PLoS One. 2026;21:e0342501.
    

    >> Share

    
    
21. RAHIMNAHAL S, Yousefizadeh S, Mohammadi Y
    Designing a novel vaccine against COVID-19 based on spike SARS-Cov-2 notable mutations using immunoinformatics approaches.
    PLoS One. 2026;21:e0334662.
    

    >> Share

    
    
22. SYABBALO E, Mpisa S, Vinikoor MJ, Wamundila M, et al
    Hepatitis B immunity and vaccine completion among adults at increased risk for hepatitis B infection in Zambia.
    PLoS One. 2026;21:e0339690.
    

    >> Share

    
    
23. KHAN A, Ahmad A, Badshah F, Ali M, et al
    Immunoinformatics-driven design of multi-epitope vaccine targeting antibiotic-resistant Salmonella typhimurium.
    PLoS One. 2026;21:e0342426.
    

    >> Share

    
    
24. RATREE S, Assavapokee N, Santibenchakul S, Sirisabya N, et al
    Reported adverse events following COVID-19 vaccination in gynecologic cancer patients in Thailand: A descriptive study.
    PLoS One. 2026;21:e0342303.
    

    >> Share

    
    

    
    Vaccine

25. SANO K, Kato H, Ryo A, Hasegawa H, et al
    Immune response and IgG subclass dynamics following repeated SARS-CoV-2 mRNA vaccination in Japanese healthcare workers.
    Vaccine. 2026;77:128396.
    

    >> Share

    
    
26. SOPHIAN A, Sulanjari D, Harumanto A
    Global implications of recent changes in U.S. vaccine policy: ethical and trust challenges for immunization programs.
    Vaccine. 2026;77:128393.
    

    >> Share

    
    
27. WILSON M, Althouse BM, Lucas A, Tort MJ, et al
    A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13.
    Vaccine. 2026;77:128350.
    

    >> Share

    
    
28. MILES S, Mourglia-Ettlin G, Chabalgoity JA
    Applied immunoinformatics in modern vaccine design: a comprehensive review of available computational tools.
    Vaccine. 2026;77:128392.
    

    >> Share

    
    
29. WHITAKER JA, Rebolledo PA, Abate G, Babu TM, et al
    The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.
    Vaccine. 2026;77:128358.
    

    >> Share

    
    
30. BOETTIGER DC, Carlson SJ, Adams SR, Tse V, et al
    Unequal access: Respiratory syncytial virus vaccine uptake by socioeconomic status among older adults in Australia.
    Vaccine. 2026;77:128395.
    

    >> Share

    
    
31. MORENO MZ, Martin JJP
    Evaluation of the impact of different notification methods for unvaccinated individuals in a ACWY meningococcal vaccination campaign.
    Vaccine. 2026;77:128383.
    

    >> Share

    
    
32. MANDARIC S, Friberg H, Gottardo R, Messer W, et al
    Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial.
    Vaccine. 2026;77:128373.
    

    >> Share

    
    
33. ANWER K, Musso L, Lasrado N, Barouch DH, et al
    Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study.
    Vaccine. 2026;77:128357.
    

    >> Share

    
    
34. TAL-SINGER R, McCreary G, Luttmann M, Williams S, et al
    Attitudes toward vaccines and antivirals for viral respiratory infections in a survey of US adults with chronic health conditions.
    Vaccine. 2026;77:128384.
    

    >> Share

    
    
35. LIANG G, Song Y, Liu Q
    Adverse events following dengue vaccine (Dengvaxia) reported to the Vaccine Adverse Event Reporting System (VAERS), 2019-2025.
    Vaccine. 2026 Feb 20:128376. doi: 10.1016/j.vaccine.2026.128376.
    

    >> Share

    
    
36. DERAZ N, Payne M, See E, Ragavapuram V, et al
    XBB 1.5 monovalent booster vaccination stimulates oral mucosal and systemic immune responses in healthy adults.
    Vaccine. 2026;77:128346.
    

    >> Share

    
    
37. PEREDO R, Savard N, Separovic L, Zhan Y, et al
    Influenza vaccination status ascertainment and vaccine effectiveness estimation: Validity of self-report for current and prior season.
    Vaccine. 2026;77:128368.
    

    >> Share

    
    
38. LI R, Vafeiadis M, Shen F, Hou Z, et al
    The role of health beliefs in COVID-19 vaccination acceptance: A Meta-analysis.
    Vaccine. 2026;77:128379.
    

    >> Share

    
    
39. FIREIZEN SM, Finkelstein A, Benisti L, Tenenbaum A, et al
    Vaccination decision-making in children with intellectual and developmental disabilities- it's a matter of trust.
    Vaccine. 2026;77:128382.
    

    >> Share

    
    
40. HUDSON A, Borgetti S, Rick AM, Laurens MB, et al
    Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials.
    Vaccine. 2026;77:128380.
    

    >> Share

    
    
41. SOHN WY, Goody SMG, Reid DW, Edwards DK, et al
    Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines.
    Vaccine. 2026;77:128394.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share